Results 31 to 40 of about 560,370 (324)

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
Background Several predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1 expression is used for stratification of non-small cell lung (NSCLC) patients, with tumor ...
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

Journal for ImmunoTherapy of Cancer, 2019
.
Kellie N. Smith, Nicolas J. Llosa, Tricia R. Cottrell, Nicholas Siegel, Hongni Fan, Prerna Suri, Hok Yee Chan, Haidan Guo, Teniola Oke, Anas H. Awan, Franco Verde, Ludmila Danilova, Valsamo Anagnostou, Ada J. Tam, Brandon S. Luber, Bjarne R. Bartlett, Laveet K. Aulakh, John-William Sidhom, Qingfeng Zhu, Cynthia L. Sears, Leslie Cope, William H. Sharfman, Elizabeth D. Thompson, Joanne Riemer, Kristen A. Marrone, Jarushka Naidoo, Victor E. Velculescu, Patrick M. Forde, Bert Vogelstein, Kenneth W. Kinzler, Nickolas Papadopoulos, Jennifer N. Durham, Hao Wang, Dung T. Le, Sune Justesen, Janis M. Taube, Luis A. Diaz Jr, Julie R. Brahmer, Drew M. Pardoll, Robert A. Anders, Franck Housseau   +40 more
doaj   +1 more source

Addressing current challenges in cancer immunotherapy with mathematical and computational modeling [PDF]

Journal of the Royal Society Interface, 14 (131): 20170150 (2017), 2017
The goal of cancer immunotherapy is to boost a patient's immune response to a tumor. Yet, the design of an effective immunotherapy is complicated by various factors, including a potentially immunosuppressive tumor microenvironment, immune-modulating effects of conventional treatments, and therapy-related toxicities.
arxiv   +1 more source

The alarmin IL33 orchestrates type 2 immune-mediated control of thymus regeneration

Nature Communications, 2023
As the primary site of T-cell development, the thymus dictates immune competency of the host. The rates of thymus function are not constant, and thymus regeneration is essential to restore new T-cell production following tissue damage from environmental ...
Emilie J. Cosway, Kieran D. James, Andrea J. White, Sonia M. Parnell, Andrea Bacon, Andrew N. J. McKenzie, W. E. Jenkinson, Graham Anderson   +7 more
doaj   +1 more source

Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic

OncoImmunology, 2023
BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory ...
Maite Alvarez, Carmen Molina, Saray Garasa, Maria C. Ochoa, Maria E Rodriguez-Ruiz, Gabriel Gomis, Assunta Cirella, Irene Olivera, Javier Glez-Vaz, Jose Gonzalez-Gomariz, carlos luri-Rey, arantza azpilikueta, Elixabet Bolaños, Alvaro Teijeira, Pedro Berraondo, Marisol Quintero, Ignacio Melero   +16 more
doaj   +1 more source

Abscopal Effects of Local Radiotherapy Are Dependent on Tumor Immunogenicity

Frontiers in Oncology, 2021
Although abscopal tumor regression remains a rare phenomenon, interest in exploiting how radiation stimulates the immune system to induce systemic abscopal response is increasing.
Jin-Zhi Lai, Jin-Zhi Lai, Yan-Yang Zhu, Ying Liu, Lin-Lin Zhou, Li Hu, Ling Chen, Qiu-Yu Zhang   +7 more
doaj   +1 more source

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Molecular Cancer, 2023
In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in only a small percentage of patients in solid cancer.
Liping Pei, Yang Liu, Lin Liu, Shuochen Gao, Xu Gao, Yudi Feng, Zhenqiang Sun, Yan Zhang, Chengzeng Wang   +8 more
semanticscholar   +1 more source

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

New England Journal of Medicine, 2010
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.
P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small, D. Penson, C. Redfern, A. Ferrari, R. Dreicer, R. Sims, Yi Xu, M. Frohlich, P. Schellhammer   +12 more
semanticscholar   +1 more source

Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy

Signal Transduction and Targeted Therapy, 2022
In recent years, immunotherapy represented by immune checkpoint inhibitors (ICIs) has led to unprecedented breakthroughs in cancer treatment. However, the fact that many tumors respond poorly or even not to ICIs, partly caused by the absence of tumor ...
W. Gao, Xuepeng Wang, Yang Zhou, Xuepeng Wang, Yan Yu   +4 more
semanticscholar   +1 more source

Immunotherapy with peptides [PDF]

Allergy, 2011
Specific allergen immunotherapy is clinically effective and disease modifying. It has a duration of effect that exceeds the treatment period and prevents both the progression of allergic rhinitis to asthma and the acquisition of new allergic sensitizations.
Daniel M. Moldaver, Mark Larché
openaire   +3 more sources